Financials in USD. Standardized financial statements.
A compact view of how Bio-Rad Laboratories, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.58B | $2.57B | $2.67B | $2.80B | $2.92B | $2.55B | $2.31B | $2.29B | $2.16B | $2.07B |
| Revenue Growth? | +0.7% | -3.9% | -4.7% | -4.1% | +14.8% | +10.1% | +0.9% | +6.0% | +4.4% | 0.0% |
| Cost of Revenue? | $1.24B | $1.19B | $1.24B | $1.23B | $1.28B | $1.11B | $1.05B | $1.07B | $972.75M | $930.09M |
| Gross Profit? | $1.34B | $1.38B | $1.43B | $1.57B | $1.64B | $1.44B | $1.26B | $1.22B | $1.19B | $1.14B |
| Gross Margin? | +52.0% | +53.7% | +53.4% | +55.9% | +56.1% | +56.5% | +54.4% | +53.5% | +55.0% | +55.0% |
| Operating Expenses? | $1.08B | $1.11B | $1.09B | $1.08B | $1.14B | $1.02B | $1.03B | $1.03B | $1.06B | $1.02B |
| Operating Income? | $270.50M | $269.00M | $337.80M | $482.62M | $500.34M | $421.33M | $229.66M | -$108.64M | $116.65M | $53.19M |
| EBITDA? | $475.90M | -$2.14B | -$654.80M | -$4.49B | $5.59B | $5.08B | $2.46B | $674.72M | $269.52M | $206.40M |
| Income Before Tax | $995.50M | -$2.34B | -$850.10M | -$4.70B | $5.45B | $4.92B | $2.26B | $507.36M | $97.81M | $41.56M |
| Income Tax Expense | $235.60M | -$498.30M | -$212.78M | -$1.08B | $1.19B | $1.10B | $502.41M | $146.36M | -$16.93M | $13.44M |
| Net Income? | $759.90M | -$1.84B | -$637.32M | -$3.63B | $4.25B | $3.81B | $1.76B | $361.00M | $114.74M | $28.13M |
| EPS? | $27.87 | $-65.36 | $-21.82 | $-121.79 | $142.61 | $127.86 | $58.93 | $12.10 | $4.12 | $0.88 |
| Diluted EPS? | $27.87 | $-65.36 | $-21.82 | $-121.79 | $140.83 | $126.20 | $58.27 | $11.94 | $4.07 | $0.88 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality